Abstract | BACKGROUND/AIMS: METHODOLOGY: Twenty-six patients with advanced CRC who were over 70 years and considered ineligible for combination chemotherapy received oral UFT 300 mg/day and UZEL 75mg/day were administered orally for 28 days followed by a 7-day rest period. Treatment was repeated every 5 weeks until disease progression. RESULTS: A total of 106 cycles of UFT/UZEL were administered (median, four cycles; range, one to twelve cycles). UFT/UZEL was well tolerated. The response rate was 11% (3 partial responses, 16 stable diseases, and 7 progressive diseases). The median progression-free survival rate was 3.9 months and the median survival time was 9.8 months. Treatment-related grade 3 and 4 adverse events were not observed. CONCLUSIONS: Oral regimen consisting of UFT/ UZEL is effective and well tolerated in elderly patients with advanced CRC who are considered ineligible for combination chemotherapy.
|
Authors | Soichi Tsutsumi, Satoru Yamaguchi, Kaori Tsuboi, Takaharu Fukasawa, Sayaka Yamaki, Takayuki Asao, Hiroyuki Kuwano |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2006 Mar-Apr
Vol. 53
Issue 68
Pg. 209-12
ISSN: 0172-6390 [Print] Greece |
PMID | 16608026
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Vitamin B Complex
- Tegafur
- Uracil
- Leucovorin
|
Topics |
- Administration, Oral
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Colorectal Neoplasms
(drug therapy, mortality, pathology)
- Drug Administration Schedule
- Female
- Humans
- Leucovorin
(administration & dosage)
- Male
- Survival Rate
- Tegafur
(administration & dosage)
- Treatment Outcome
- Uracil
(administration & dosage)
- Vitamin B Complex
(administration & dosage)
|